Traité sur la vaccine ou Recherches historiques et critiques sur les résultats obtenus par les vaccinations et revaccinations ... /

Mode of access: Internet.

Nouveau traité de la vaccine et des éruptions varioleuses /

Mode of access: Internet.

Survey of antimalarial agents. Chemotherapy of plasmodium gallinaceum infections; toxicity; correlation of structure and action

Mode of access: Internet.

Compensation for vaccine-related injuries : a technical memorandum.

Mode of access: Internet.

Revue internationale de la vaccine.

Publication suspended 1914-1919.

Epidemiologic studies for vaccine development

"PB 176 814."

Mémoire sur la vaccine primitive /

En port.: Estrait des Mémoires de l'Académie Royale de Médecine de Belgique,

Management audit of the flu vaccine procurement and the I-Save Rx Program /

This audit concluded that Illinois' preocurement of flu vaccine was not adequately planned or monitored and led to financial liability for vaccine that the state did not receive. The I-Save Rx Program, which imports prescription drugs into the United States from other countries, and was found to be in violation of federal law is also covered in this report.

A survey of antimalarial drugs, 1941-1945 ....

Mode of access: Internet.

Uber Combination von Blatternschutzimpfung, Masern und multipler embolischer Gangran der Haut und Schleimhaute, zugleich ein Beitrag zur Frage der generalisirten Vaccine.

Mode of access: Internet.

The Impact of a Group Health Cooperative HPV Vaccination Promotion Program on Initiation of the HPV Vaccine

Thesis (Master's)--University of Washington, 2016-06

Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens

This study demonstrates the effectiveness of a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens by use of lipid core peptide (LCP) technology. An LCP formulation incorporating two different protective epitopes of the surface antiphagocytic M protein of group A streptococci (GAS)-the causative agents of rheumatic fever and subsequent rheumatic heart disease-was tested in a murine parenteral immunization and GAS challenge model. Mice were immunized with the LCP-GAS formulation, which contains an M protein amino-terminal type-specific peptide sequence (8830) in combination with a conserved non-host-cross-reactive carboxy-terminal C-region peptide sequence (J8) of the M protein. Our data demonstrated immunogenicity of the LCP-8830-J8 formulation in B10.BR mice when coadministered in complete Freund's adjuvant and in the absence of a conventional adjuvant. In both cases, immunization led to induction of high-titer GAS peptide-specific serum immunoglobulin G antibody responses and induction of highly opsonic antibodies that did not cross-react with human heart tissue proteins. Moreover, mice were completely protected from GAS infection when immunized with LCP-8830-J8 in the presence or absence of a conventional adjuvant. Mice were not protected, however, following immunization with an LCP formulation containing a control peptide from a Schistosoma sp. These data support the potential of LCP technology in the development of novel self-adjuvanting multi-antigen component vaccines and point to the potential application of this system in the development of human vaccines against infectious diseases.